Composite poly(vinyl alcohol)/poly(vinyl acetate) electrospun nanofibrous mats as a novel wound dressing matrix for controlled release of drugs

Figures & data

Figure 1 SEM photographs of electrospun nanofibers without drug and with 10% w/w drug loaded: A, B) PVA; C, D) PVAc; E, F) a 50:50 blend of PVA/PVAc; G, H) effect of drug loading on appearance of PVA/PVAc blend nanofiber mats.

Abbreviations: CipHCl, ciprofloxacin HCl; PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.

Figure 2 Effect of CipHCl on A) the diameter of nanofibers (n = 100) and B) the solution viscosity (n = 3).

Abbreviations: PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.

Figure 3 X-ray diffraction of A) CipHCl powder, B) pure 50:50 PVA/PVAc nanofiber mat, and C) 50:50 PVA/PVAc nanofiber mat loaded with 10% w/w drug.

Abbreviations: CipHCl, ciprofloxacin HCl; PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.

Figure 4 Effect of the type of polymer and/or the drug content A) on the degree of swelling (%) and B) on the weight loss (%) of PVA, PVAc and a 50:50 blend nanofiber mat, and C) effect of the thickness of blend nanofiber mats on the degree of swelling (%) (n = 3).

Abbreviations: PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.

Figure 5 Effect of drug content on release profiles of CipHCl from PVAc (32% w/v) electrospun nanofiber mats vs time (n = 3).

Abbreviations: CipHCl, ciprofloxacin HCl; PVAc, polyvinyl acetate.

Figure 6 Effect of drug content on release profiles of CipHCl from PVA (5% w/v) electrospun nanofiber mats vs time (n = 3).

Abbreviations: CipHCl, ciprofloxacin HCl; PVAc, polyvinyl acetate.

Figure 7 Effect of polymers blending on the release profiles of CipHCl from medicated electrospun nanofiber mats containing 10% w/w CipHCl vs time (n = 3).

Abbreviations: CipHCl, ciprofloxacin HCl; PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.

Figure 8 Effect of thickness on the release behavior from medicated electrospun nanofiber mats of PVA:PVAc (50:50) containing 10% w/w CipHCl vs time (n = 3).

Abbreviations: CipHCl, ciprofloxacin HCl; PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.

Table 1 Diffusion constant (n) and regression coefficient of ciprofloxacin HCl release from PVA, PVAc, and blend nanofiber mats calculated by Peppas equation (M_t/M_∞ = ktⁿ) (n = 3)

Nanofiber type	Thickness of mat (μm)	CipHCL (% w/w)	R^2± SD	N ± SD
PVA	300–360	5	0.99 ± 0.04	0.15 ± 0.00
		10	0.99 ± 0.02	0.27 ± 0.01
		5	0.95 ± 0.02	0.15 ± 0.00
PVAc	300–360	10	0.93 ± 0.01	0.083 ± 0.00
	100–140		0.85 ± 0.06	0.010 ± 0.01
PVA:PVAc (50:50)	300–360	10	0.95 ± 0.04	0.18 ± 0.00
	690–780		0.97 ± 0.06	0.19 ± 0.02

Abbreviations: CipHCl, ciprofloxacin HCl; PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.

Table 2 Regression coefficients of different mathematical models fitted to the release of ciprofloxacin HCl from different nanofibers with the thickness of 300 to 360 μm (n = 3)

Nanofibers type	CipHCL (% w/w)	Zero order	First order	Higuchi	Hixon–Crowell
PVA	5	0.65 ± 0.05	0.79 ± 0.04	0.92 ± 0.06	0.28 ± 0.05
	10	0.71 ± 0.01	0.85 ± 0.01	0.94 ± 0.02	0.36 ± 0.04
PVAc before 72 h	5	0.35 ± 0.04	0.41 ± 0.06	0.68 ± 0.02	0.29 ± 0.03
	10	0.45 ± 0.06	0.45 ± 0.03	0.78 ± 0.03	0.30 ± 0.02
PVAc after 72 h	5	0.96 ± 0.04	0.93 ± 0.01	0.94 ± 0.03	0.98 ± 0.03
	10	0.98 ± 0.05	0.92 ± 0.01	0.95 ± 0.02	0.99 ± 0.06
PVA:PVAc (50:50)	10	0.66 ± 0.06	0.72 ± 0.15	0.90 ± 0.04	0.38 ± 0.09

Abbreviations: CipHCl, ciprofloxacin HCl; PVA, polyvinyl alcohol; PVA/PVAc, polyvinyl acetate.